Asparaginase revisited

References

• Kidd JG. Regression of transplanted lymphomas induced in vivo by means of normal guinea pig serum. I. Course of transplanted cancers of various kinds in mice and rats given guinea pig serum, horse serum, or rabbit serum. J Exp Med 1953;98:565–582.
   PubMed Web of Science ®Google Scholar
• Broome JD. L-asparaginase: the evolution of a new tumor inhibitory agent. Trans NY Acad Sci 1968;30:690–704.
   PubMedGoogle Scholar
• Dolowy WC, Henson D, Cornet J, Sellin H. Toxic and antineoplastic effects of L-asparaginase. Study of mice with lymphoma and normal monkeys and report on a child with leukemia. Cancer 1966;19:1813–1819.
   PubMed Web of Science ®Google Scholar
• Adamson RH, Fabro S. Antitumor activity and other biologic properties of L-asparaginase (NSC-109229)–a review. Cancer Chemother Rep 1968;52:617–626.
   PubMedGoogle Scholar
• Pieters R, Hunger SP, Boos J, et al. L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer 2010 Sep 7. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Wriston JC Jr, Yellin TO. L-asparaginase: a review. Adv Enzymol Relat Areas Mol Biol 1973;39:185–248.
   PubMedGoogle Scholar
• Del Casale T, Sollitti P, Chesney RH. Cytoplasmic L-asparaginase: isolation of a defective strain and mapping of ansA. J Bacteriol 1983;154:513–515.
   PubMed Web of Science ®Google Scholar
• Whitecar JP Jr, Bodey GP, Harris JE, Freireich EJ. L-asparaginase. N Engl J Med 1970;282:732–734.
   PubMed Web of Science ®Google Scholar
• Muller HJ, Boos J. Use of L-asparaginase in childhood ALL. Crit Rev Oncol Hematol 1998;28:97–113.
   PubMed Web of Science ®Google Scholar
• Boos J, Werber G, Ahlke E, et al. Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations. Eur J Cancer 1996;32A:1544–1550.
   PubMed Web of Science ®Google Scholar
• Zalewska-Szewczyk B, Andrzejewski W, Mlynarski W, et al. The anti-asparagines antibodies correlate with L-asparagines activity and may affect clinical outcome of childhood acute lymphoblastic leukemia. Leuk Lymphoma 2007;48:931–936.
   PubMed Web of Science ®Google Scholar
• Cheung NK, Chau IY, Coccia PF. Antibody response to Escherichia coli L-asparaginase. Prognostic significance and clinical utility of antibody measurement. Am J Pediatr Hematol Oncol 1986;8:99–104.
   PubMedGoogle Scholar
• Schwartz MK. The distribution and clearance of L-asparaginase. Recent Results Cancer Res 1970;33:58–63.
   PubMedGoogle Scholar
• Capizzi RL, Bertino JR, Handschumacher RE. L-asparaginase. Annu Rev Med 1970;21:433–444.
   PubMed Web of Science ®Google Scholar
• Boos J. Pharmacokinetics and drug monitoring of L-asparaginase treatment. Int J Clin Pharmacol Ther 1997;35:96–98.
   PubMed Web of Science ®Google Scholar
• Riccardi R, Holcenberg JS, Glaubiger DL, Wood JH, Poplack DG. L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans. Cancer Res 1981;41:4554–4558.
   PubMed Web of Science ®Google Scholar
• Vieira Pinheiro JP, Wenner K, Escherich G, et al. Serum asparaginase activities and asparagine concentrations in the cerebrospinal fluid after a single infusion of 2,500 IU/m(2) PEG asparaginase in children with ALL treated according to protocol COALL-06–97. Pediatr Blood Cancer 2006;46:18–25.
   PubMed Web of Science ®Google Scholar
• Gentili D, Conter V, Rizzari C, et al. L-asparagine depletion in plasma and cerebro-spinal fluid of children with acute lymphoblastic leukemia during subsequent exposures to Erwinia L-asparaginase. Ann Oncol 1996;7:725–730.
   PubMed Web of Science ®Google Scholar
• Rizzari C, Zucchetti M, Conter V, et al. L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E. coli L-asparaginase as first exposure. Ann Oncol 2000;11:189–193.
   PubMed Web of Science ®Google Scholar
• Pieters R, Appel I, Kuehnel HJ, et al. Pharmacokinetics, pharmacodynamics, efficacy, and safety of a new recombinant asparaginase preparation in children with previously untreated acute lymphoblastic leukemia: a randomized phase 2 clinical trial. Blood 2008;112:4832–4838.
   PubMed Web of Science ®Google Scholar
• Ho DH, Whitecar JP Jr, Luce JK, Frei E III. L-asparagine requirement and the effect of L-asparaginase on the normal and leukemic human bone marrow. Cancer Res 1970;30:466–472.
   PubMed Web of Science ®Google Scholar
• Appel IM, Kazemier KM, Boos J, et al. Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window study. Leukemia 2008;22:1665–1679.
   PubMed Web of Science ®Google Scholar
• Kaspers GJ, Veerman AJ, Pieters R, et al. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood 1997;90:2723–2729.
   PubMed Web of Science ®Google Scholar
• Pieters R, den Boer ML, Durian M, et al. Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia–implications for treatment of infants. Leukemia 1998;12:1344–1348.
   PubMed Web of Science ®Google Scholar
• Pinheiro JP, Boos J. The best way to use asparaginase in childhood acute lymphatic leukaemia–still to be defined? Br J Haematol 2004;125:117–127.
   PubMed Web of Science ®Google Scholar
• Avramis VI, Panosyan EH. Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future. Clin Pharmacokinet 2005;44:367–393.
   PubMed Web of Science ®Google Scholar
• Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91–01. Blood 2001;97:1211–1218.
   PubMed Web of Science ®Google Scholar
• Ohnuma T, Holland JF, Freeman A, Sinks LF. Biochemical and pharmacological studies with asparaginase in man. Cancer Res 1970;30:2297–2305.
   PubMed Web of Science ®Google Scholar
• Caruso V, Iacoviello L, Di CA, et al. Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood 2006;108:2216–2222.
   PubMed Web of Science ®Google Scholar
• Abbott LS, Deevska M, Fernandez CV, et al. The impact of prophylactic fresh-frozen plasma and cryoprecipitate on the incidence of central nervous system thrombosis and hemorrhage in children with acute lymphoblastic leukemia receiving asparaginase. Blood 2009;114:5146–5151.
   PubMed Web of Science ®Google Scholar
• Athale UH, Siciliano SA, Crowther M, Barr RD, Chan AK. Thromboembolism in children with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute protocols: effect of age and risk stratification of disease. Br J Haematol 2005;129:803–810.
   PubMed Web of Science ®Google Scholar
• Muller HJ, Beier R, Loning L, et al. Pharmacokinetics of native Escherichia coli asparaginase (Asparaginase Medac) and hypersensitivity reactions in ALL-BFM 95 reinduction treatment. Br J Haematol 2001;114:794–799.
   PubMed Web of Science ®Google Scholar
• Avramis VI, Tiwari PN. Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia. Int J Nanomed 2006;1:241–254.
   PubMed Web of Science ®Google Scholar
• Reinert RB, Oberle LM, Wek SA, et al. Role of glutamine depletion in directing tissue-specific nutrient stress responses to L-asparaginase. J Biol Chem 2006;281:31222–31233.
   PubMed Web of Science ®Google Scholar
• Casadevall N. Pure red cell aplasia and anti-erythropoietin antibodies in patients treated with epoetin. Nephrol Dial Transplant 2003;18(Suppl. 8):viii37–viii41.
   PubMedGoogle Scholar
• Avramis VI, Sencer S, Periclou AP, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood 2002;99:1986–1994.
   PubMed Web of Science ®Google Scholar
• Woo MH, Hak LJ, Storm MC, et al. Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol 2000;18:1525–1532.
   PubMed Web of Science ®Google Scholar
• Larson RA, Fretzin MH, Dodge RK, Schiffer CA. Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia. Leukemia 1998;12:660–665.
   PubMed Web of Science ®Google Scholar
• Hawkins DS, Park JR, Thomson BG, et al. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia. Clin Cancer Res 2004;10:5335–5341.
   PubMed Web of Science ®Google Scholar
• Wang B, Relling MV, Storm MC, et al. Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients. Leukemia 2003;17:1583–1588.
   PubMed Web of Science ®Google Scholar
• Albertsen BK, Schroder H, Jakobsen P, et al. Antibody formation during intravenous and intramuscular therapy with Erwinia asparaginase. Med Pediatr Oncol 2002;38:310–316.
   PubMedGoogle Scholar
• Killander D, Dohlwitz A, Engstedt L, et al. Hypersensitive reactions and antibody formation during L-asparaginase treatment of children and adults with acute leukemia. Cancer 1976;37:220–228.
   PubMed Web of Science ®Google Scholar
• Armstrong JK, Hempel G, Koling S, et al. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer 2007;110:103–111.
   PubMed Web of Science ®Google Scholar
• Vrooman LM, Supko JG, Neuberg DS, et al. Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2010;54:199–205.
   PubMed Web of Science ®Google Scholar
• Billett AL, Carls A, Gelber RD, Sallan SE. Allergic reactions to Erwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions to Escherichia coli asparaginase. Cancer 1992;70:201–206.
   PubMed Web of Science ®Google Scholar
• Silverman LB, Supko JG, Stevenson KE, et al. Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia. Blood 2010;115:1351–1353.
   PubMed Web of Science ®Google Scholar
• Albertsen BK, Jakobsen P, Schroder H, Schmiegelow K, Carlsen NT. Pharmacokinetics of Erwinia asparaginase after intravenous and intramuscular administration. Cancer Chemother Pharmacol 2001;48:77–82.
   PubMed Web of Science ®Google Scholar
• Albertsen BK, Schroder H, Ingerslev J, et al. Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase Medac: pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation system. Br J Haematol 2001;115:983–990.
   PubMed Web of Science ®Google Scholar
• Schrey D, Borghorst S, Lanvers-Kaminsky C, et al. Therapeutic drug monitoring of asparaginase in the ALL-BFM 2000 protocol between 2000 and 2007. Pediatr Blood Cancer 2010;54:952–958.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000;18:547–561.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Thomas D, O'Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 2004;101:2788–2801.
   PubMed Web of Science ®Google Scholar
• Ertel IJ, Nesbit ME, Hammond D, Weiner J, Sather H. Effective dose of L-asparaginase for induction of remission in previously treated children with acute lymphocytic leukemia: a report from Children's Cancer Study Group. Cancer Res 1979;39:3893–3896.
   PubMed Web of Science ®Google Scholar
• Amylon MD, Shuster J, Pullen J, et al. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia 1999;13:335–342.
   PubMed Web of Science ®Google Scholar
• Pession A, Valsecchi MG, Masera G, et al. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia. J Clin Oncol 2005;23:7161–7167.
   PubMed Web of Science ®Google Scholar
• Moghrabi A, Levy DE, Asselin B, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95–01 for children with acute lymphoblastic leukemia. Blood 2007;109:896–904.
   PubMed Web of Science ®Google Scholar
• Eden OB, Shaw MP, Lilleyman JS, Richards S. Non-randomised study comparing toxicity of Escherichia coli and Erwinia asparaginase in children with leukaemia. Med Pediatr Oncol 1990;18:497–502.
   PubMedGoogle Scholar
• Sallan SE, Hitchcock-Bryan S, Gelber R, et al. Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia. Cancer Res 1983;43:5601–5607.
   PubMed Web of Science ®Google Scholar
• Ahlke E, Nowak-Gottl U, Schulze-Westhoff P, et al. Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia. Br J Haematol 1997;96:675–681.
   PubMed Web of Science ®Google Scholar
• Asselin BL, Whitin JC, Coppola DJ, et al. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol 1993;11:1780–1786.
   PubMed Web of Science ®Google Scholar
• Keating MJ, Holmes R, Lerner S, Ho DH. L-asparaginase and PEG asparaginase–past, present, and future. Leuk Lymphoma 1993;10(Suppl.):153–157.
   PubMedGoogle Scholar
• Douer D, Yampolsky H, Cohen LJ, et al. Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood 2007;109:2744–2750.
   PubMed Web of Science ®Google Scholar
• Vieira Pinheiro JP, Ahlke E, Nowak-Gottl U, et al. Pharmacokinetic dose adjustment of Erwinia asparaginase in protocol II of the paediatric ALL/NHL-BFM treatment protocols. Br J Haematol 1999;104:313–320.
   PubMed Web of Science ®Google Scholar
• Fu CH, Sakamoto KM. PEG-asparaginase. Expert Opin Pharmacother 2007;8:1977–1984.
   PubMed Web of Science ®Google Scholar
• Vieira Pinheiro JP, Muller HJ, Schwabe D, et al. Drug monitoring of low-dose PEG-asparaginase (Oncaspar) in children with relapsed acute lymphoblastic leukaemia. Br J Haematol 2001;113:115–119.
   PubMed Web of Science ®Google Scholar
• Woo MH, Hak LJ, Storm MC, et al. Cerebrospinal fluid asparagine concentrations after Escherichia coli asparaginase in children with acute lymphoblastic leukemia. J Clin Oncol 1999;17:1568–1573.
   PubMed Web of Science ®Google Scholar
• Avramis VI, Spence SA. Clinical pharmacology of asparaginases in the United States: asparaginase population pharmacokinetic and pharmacodynamic (PK-PD) models (NONMEM) in adult and pediatric ALL patients. J Pediatr Hematol Oncol 2007;29:239–247.
   PubMed Web of Science ®Google Scholar
• Muller HJ, Beier R, da Palma JC, et al. PEG-asparaginase (Oncaspar) 2500 U/m(2) BSA in reinduction and relapse treatment in the ALL/NHL-BFM protocols. Cancer Chemother Pharmacol 2002;49:149–154.
   PubMed Web of Science ®Google Scholar
• Ettinger LJ, Kurtzberg J, Voute PA, Jurgens H, Halpern SL. An open-label, multicenter study of polyethylene glycol-L-asparaginase for the treatment of acute lymphoblastic leukemia. Cancer 1995;75:1176–1181.
   PubMed Web of Science ®Google Scholar
• Abshire TC, Pollock BH, Billett AL, Bradley P, Buchanan GR. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study. Blood 2000;96:1709–1715.
   PubMed Web of Science ®Google Scholar
• Abuchowski A, Kazo GM, Verhoest CR Jr, et al. Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates. Cancer Biochem Biophys 1984;7:175–186.
   PubMedGoogle Scholar
• Kurre HA, Ettinger AG, Veenstra DL, et al. A pharmacoeconomic analysis of pegaspargase versus native Escherichia coli L-asparaginase for the treatment of children with standard-risk, acute lymphoblastic leukemia: the Children's Cancer Group study (CCG-1962). J Pediatr Hematol Oncol 2002;24:175–181.
   PubMed Web of Science ®Google Scholar
• Capizzi RL. Asparaginase revisited. Leuk Lymphoma 1993;10(Suppl.):147–150.
   PubMedGoogle Scholar
• Hunault-Berger M, Chevallier P, Delain M, et al. Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study. Haematologica 2008;93:1488–1494.
   PubMed Web of Science ®Google Scholar
• Hernandez-Espinosa D, Minano A, Martinez C, et al. L-asparaginase-induced antithrombin type I deficiency: implications for conformational diseases. Am J Pathol 2006;169:142–153.
   PubMed Web of Science ®Google Scholar
• Hamidi M, Zarrin A, Foroozesh M, Mohammadi-Samani S. Applications of carrier erythrocytes in delivery of biopharmaceuticals. J Control Release 2007;118:145–160.
   PubMed Web of Science ®Google Scholar
• Kwon YM, Chung HS, Moon C, et al. L-asparaginase encapsulated intact erythrocytes for treatment of acute lymphoblastic leukemia (ALL). J Control Release 2009;139:182–189.
   PubMed Web of Science ®Google Scholar
• Kravtzoff R, Ropars C, Laguerre M, Muh JP, Chassaigne M. Erythrocytes as carriers for L-asparaginase. Methodological and mouse in-vivo studies. J Pharm Pharmacol 1990;42:473–476.
   PubMed Web of Science ®Google Scholar
• Kravtzoff R, Colombat PH, Desbois I, et al. Tolerance evaluation of L-asparaginase loaded in red blood cells. Eur J Clin Pharmacol 1996;51:221–225.
   PubMed Web of Science ®Google Scholar
• Narta UK, Kanwar SS, Azmi W. Pharmacological and clinical evaluation of L-asparaginase in the treatment of leukemia. Crit Rev Oncol Hematol 2007;61:208–221.
   PubMed Web of Science ®Google Scholar
• Mitchell LG, Andrew M, Hanna K, et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study. Cancer 2003;97:508–516.
   PubMed Web of Science ®Google Scholar
• Mitchell L, Andrew M, Hanna K, et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving L-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thromb Haemost 2003;90:235–244.
   PubMed Web of Science ®Google Scholar
• Avramis VI, Martin-Aragon S, Avramis EV, Asselin BL. Pharmacoanalytical assays of Erwinia asparaginase (erwinase) and pharmacokinetic results in high-risk acute lymphoblastic leukemia (HR ALL) patients: simulations of Erwinase population PK-PD models. Anticancer Res 2007;27:2561–2572.
   PubMed Web of Science ®Google Scholar
• Albertsen BK, Schroder H, Jakobsen P, et al. Monitoring of Erwinia asparaginase therapy in childhood ALL in the Nordic countries. Br J Clin Pharmacol 2001;52:433–437.
   PubMed Web of Science ®Google Scholar
• Rizzari C, Citterio M, Zucchetti M, et al. A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia. Haematologica 2006;91:24–31.
   PubMed Web of Science ®Google Scholar